Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
BDNF 627 CAMPTOTHECIN CHEMBL65 NCI 10428835
BDNF 627 DIETHYLSTILBESTROL CHEMBL411 NCI 17292805
BDNF 627 IMIPRAMINE CHEMBL11 NCI 16522641
BDNF 627 K-252A CHEMBL281948 NCI 16797499
BDNF 627 NALOXONE CHEMBL80 NCI 12359151
BDNF 627 NYSTATIN CHEMBL229383 NCI 12941963
BDNF 627 VENLAFAXINE CHEMBL637 NCI 14978196
BDNF 627 FLUOXETINE CHEMBL41 PharmGKB
BDNF 627 METHADONE CHEMBL651 NCI 18182069
BDNF 627 FLURBIPROFEN CHEMBL563 NCI 16531049
BDNF 627 GENTAMICIN CHEMBL3039597 NCI 10536212
BDNF 627 ADAPALENE CHEMBL1265 NCI 18394312
BDNF 627 HALOPERIDOL CHEMBL54 NCI 12393228
BDNF 627 TROGLITAZONE CHEMBL408 NCI 17924870
BDNF 627 ARSENIC TRIOXIDE CHEMBL1200978 NCI 16711005
BDNF 627 CHLORPROMAZINE CHEMBL71 NCI 18408624
BDNF 627 INOSITOL CHEMBL1222251 NCI 16286649
BDNF 627 LEVODOPA CHEMBL1009 NCI 15081599
BDNF 627 PROPRANOLOL CHEMBL27 NCI 15598146
BDNF 627 THYROGLOBULIN CHEMBL1201650 NCI 8895887
BDNF 627 GLUCAGON CHEMBL266481 NCI 17924870
BDNF 627 CORTICOTROPIN CHEMBL1201610 NCI 16330021
BDNF 627 EPOETIN BETA CHEMBL2109092 NCI 15816864
BDNF 627 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 7982951, 18563704, 18815270
BDNF 627 FLUOROURACIL CHEMBL185 NCI 18702703
BDNF 627 CETUXIMAB CHEMBL1201577 NCI 16651634
BDNF 627 DIDANOSINE CHEMBL1460 NCI 17616550
BDNF 627 INDOMETHACIN CHEMBL6 NCI 16956981
BDNF 627 IONOMYCIN CHEMBL501617 NCI 12038986
BDNF 627 LITHIUM CHEMBL2146126 NCI 16300803
BDNF 627 METHYLPREDNISOLONE CHEMBL650 NCI 14966352
BDNF 627 SIMVASTATIN CHEMBL1064 NCI 18047562
BDNF 627 STAUROSPORINE CHEMBL388978 NCI 10683584
BDNF 627 ZINC SULFATE CHEMBL1200929 NCI 16962724
BDNF 627 TRICHOSTATIN CHEMBL99 NCI 17392473
BDNF 627 DESIPRAMINE CHEMBL72 PharmGKB
BDNF 627 DACTINOMYCIN CHEMBL1554 NCI 10899924
BDNF 627 CAPSAICIN CHEMBL294199 NCI 10430952
BDNF 627 CURCUMIN CHEMBL116438 NCI 17617388, 18420184
BDNF 627 PROXYPHYLLINE CHEMBL37390 NCI 16026835
BDNF 627 PILOCARPINE CHEMBL550 NCI 15183516
BDNF 627 PROPYLTHIOURACIL CHEMBL1518 NCI 11077070
BDNF 627 VERTEPORFIN CHEMBL2218885 NCI 15505074
BDNF 627 VINCRISTINE CHEMBL90555 NCI 15569250
BDNF 627 SODIUM CHLORIDE CHEMBL1200574 NCI 12742641
BDNF 627 ESTRADIOL BENZOATE CHEMBL282575 NCI 11923430
BDNF 627 COLCHICINE CHEMBL107 NCI 1946455
BDNF 627 MIFEPRISTONE CHEMBL1276308 NCI 17464718
BDNF 627 PACLITAXEL CHEMBL428647 NCI 16778834
BDNF 627 TOPOTECAN CHEMBL84 NCI 15569250
BDNF 627 VASOPRESSIN CHEMBL373742 NCI 16457953
BDNF 627 NICOTINE CHEMBL3 NCI 16790237
BDNF 627 LIOTHYRONINE SODIUM CHEMBL1201119 NCI 8288635
BDNF 627 ANTIBIOTIC CHEMBL606111 NCI 14736076
BDNF 627 BACLOFEN CHEMBL701 NCI 17074039
BDNF 627 BORTEZOMIB CHEMBL325041 NCI 15657181
BDNF 627 DITIOCARB CHEMBL961 NCI 17052849
BDNF 627 DOXORUBICIN CHEMBL53463 NCI 10728907
BDNF 627 FULVESTRANT CHEMBL1358 NCI 17044036
BDNF 627 ANAKINRA CHEMBL1201570 NCI 14580934
BDNF 627 TRAMADOL CHEMBL1237044 NCI 15464068
BDNF 627 DONEPEZIL CHEMBL502 NCI 17990049
BDNF 627 LIDOCAINE CHEMBL79 NCI 16210356
BDNF 627 TARGININE CHEMBL256147 NCI 10215909
BDNF 627 NICARDIPINE CHEMBL1484 NCI 10748141
BDNF 627 CHEMBL1234621 CHEMBL1234621 NCI 16903870
BDNF 627 HYDROGEN PEROXIDE CHEMBL71595 NCI 9406937
BDNF 627 GEMFIBROZIL CHEMBL457 NCI 17823123

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
BDNF rs6265 CC methylphenidate efficacy yes A significant association at the Bonferroni-corrected level was found between the relative frequency of CGI-S 1 or 2 status post-treatment and homozygosity of the Val allele of the BDNF Val66Met polymorphism (p=0.0002) Genotype CC is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes CT + TT. 21733227 1450376988
BDNF rs6265 CT antidepressants efficacy yes Genotype CT is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CC + TT. 23733030 982028611
BDNF rs2030324 G methadone efficacy yes This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for "increased risk of poorer response". There were 23 nonresponders and 68 responders. Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A. 18182069 982006921
BDNF rs6265 TT paroxetine efficacy yes Remained significant after Bonferroni correction. Genotype TT is associated with decreased response to paroxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT. 23619509 982009519
BDNF rs6265 T escitalopram efficacy no Allele T is not associated with response to escitalopram in people with Depression as compared to allele C. 31721892 1451148561
BDNF rs988748 C methadone efficacy yes This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for "increased risk of poorer response". There were 23 nonresponders and 68 responders. Allele C is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele G. 18182069 982006910
BDNF rs6265 T paroxetine efficacy no Additionally, no correlation was observed between BDNF Val66Met polymorphism and serum BDNF levels at T0. Allele T is not associated with response to paroxetine or sertraline in people with Depressive Disorder, Major as compared to allele C. 21338649 827815008
BDNF rs6265 C fluoxetine efficacy no Information is minimal because full-text was not accessible. Allele C is not associated with response to fluoxetine in people with Depressive Disorder, Major as compared to allele T. 20016225 981501007
BDNF rs7103411 TT citalopram efficacy yes The association was with worse treatment outcome over 6 weeks only in clinical subtypes such as melancholic depression. Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype CC. 19236730 981861633
BDNF rs6265 TT mirtazapine efficacy no Association was not significant after Bonferroni correction. Genotype TT is not associated with response to mirtazapine in people with Depressive Disorder, Major as compared to genotypes CC + CT. 23619509 982009615
BDNF rs1491850 CC methadone dosage no This association was statistically significant after permutation analysis based on 40,000 replicates, but not statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction). Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotypes CT + TT. 23651024 982032084
BDNF rs7934165 AA methadone dosage no This association was not statistically significant after permutation analysis based on 40,000 replicates, or statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction). Note; this SNP was in LD with rsrs10835210 (r^2>0.7) and not independent. Alleles were reported as T/C, here they are complemented with A representing T and G representing C for the positive chromosomal strand. Genotype AA is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AG + GG. 23651024 982032054
BDNF rs6265 CT + TT antipsychotics efficacy yes The T allele is associated with increased odds of resistance to antipsychotic treatment. Resistance was assessed by whether patients were taking clozapine, since clozapine is indicated for patients poorly responsive or resistant to first-line treatments. Please note alleles have been complemented to the plus chromosomal strand. Genotypes CT + TT is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype CC. 23433505 1183697782
BDNF rs7124442 CC antidepressants efficacy no This SNP did not affect response to antidepressants. Response was defined as a 50% reduction on the Hamilton Depression Rating Scale (HAMD-21) from baseline to week 6. Naturalistic study, no information was provided on the specific drugs administered. Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT. 22965830 1184167140
BDNF rs6265 CC antidepressants efficacy no This SNP did not affect response to antidepressants. Response was defined as a 50% reduction on the Hamilton Depression Rating Scale (HAMD-21) from baseline to week 6. Naturalistic study, no information was provided on the specific drugs administered. Please note alleles have been complemented to the plus chromosomal strand. Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT. 22965830 1184167136
BDNF rs6265 CC + CT paroxetine efficacy yes Patients were grouped by gender, the data revealed that the significant difference between G allele carriers in responder vs non-responder existed only in women (P = 0.019) and not in men (P = 0.255). To ensure the accuracy of the results, multiple linear regression models were applied, and 3 SNPs were still identified as significant determinants of paroxetine clinical response (P rs 6265 = 0.001, P rs 2973049 = 0.011, and P rs 2216711 = 0.010). According to all of the analyses, the variability in paroxetine clinical response could be attributed to plasma concentration and SNPs. Genotypes CC + CT is associated with decreased response to paroxetine in women with Depressive Disorder, Major as compared to genotype TT. 24577123 1184755018
BDNF rs6265 CC olanzapine efficacy yes The CC genotype (referred to as Val/Val in the paper) was associated with an increased likelihood of response to olanzapine treatment, as compared to those with the CT or TT genotype (Val/Met or Met/Met). Response defined as at least a 50% reduction in the initial Positive and Negative Syndrome Scale (PANSS) total and subscale scores after 8 weeks of treatment. Significant results were seen for the PANSS total and PANSS positive subscale scores, but not for PANSS negative or PANSS general psychopathology scores. Genotype CC is associated with increased response to olanzapine in people with Schizophrenia as compared to genotypes CT + TT. 24595507 1446896603
BDNF rs10835210 A heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele A is not associated with response to heroin as compared to allele C. 28692418 1450827434
BDNF rs6265 CC escitalopram efficacy no The authors considered the relationship between mean methylation in the BDNF gene with genotype and found that it was significant - however mean methylation in BDNF gene with response to escitalopram was not significant. Genotype CC is not associated with response to escitalopram in people with Depressive Disorder as compared to genotypes CT + TT. 29748862 1449311464
BDNF rs6265 T heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Please note that alleles have been complemented to the positive strand. Allele T is not associated with response to heroin as compared to allele C. 28692418 1450827404
BDNF rs6265 C modafinil efficacy no No significant association between this variant and Treatment Effectiveness Scores following modafinil treatment compared to placebo. Allele C is not associated with response to modafinil in people with methamphetamine dependence as compared to allele T. 22217949 1450813976
BDNF rs6265 C risperidone efficacy no Please note that alleles have been complemented to the positive strand. Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 28696411 1450928280
BDNF rs16917234 C heroin toxicity no No significant association between this variant and positive or negative response to first use of heroin. Allele C is not associated with response to heroin as compared to allele T. 28692418 1450827439
BDNF rs11030104 AG + GG antipsychotics efficacy yes The G allele is associated with increased odds of resistance to antipsychotic treatment. Resistance was assessed by whether patients were taking clozapine, since clozapine is indicated for patients poorly responsive or resistant to first-line treatments. Please note alleles have been complemented to the plus chromosomal strand. Genotypes AG + GG is associated with increased resistance to antipsychotics in people with Schizophrenia as compared to genotype AA. 23433505 1183697770
BDNF rs7103411 CC antidepressants efficacy no This SNP did not affect response to antidepressants. Response was defined as a 50% reduction on the Hamilton Depression Rating Scale (HAMD-21) from baseline to week 6. Naturalistic study, no information was provided on the specific drugs administered. Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT. 22965830 1184167131
BDNF rs7103411 TT escitalopram efficacy no The authors considered the relationship between mean methylation in the BDNF gene with genotype and found that it was significant - however mean methylation in BDNF gene with response to escitalopram was not significant. Genotype TT is not associated with response to escitalopram in people with Depressive Disorder as compared to genotypes CC + CT. 29748862 1449311473
BDNF rs7124442 TT citalopram efficacy yes The association was with worse treatment outcome over 6 weeks and this applied particularly to anxious depression, for which p = 0.003. Genotype TT is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotypes CC + CT. 19236730 981861603
BDNF rs10835210 CC methadone dosage no This association was statistically significant after permutation analysis based on 40,000 replicates, but not statistically significant after adjusting for testing for multiple SNPs (Bonferroni correction). Note; this SNP was in LD with rs7934165 (r^2>0.7) and not independent. Genotype CC is associated with increased dose of methadone in people with Heroin Dependence as compared to genotypes AA + AC. 23651024 982032025
BDNF rs11030119 G methadone efficacy yes This association is not found for the SNP alone, but for a haplotype containing 6 SNPs (rs7127507, rs1967554, rs11030118, rs988748, rs2030324 and rs11030119). The associated OR is for "increased risk of poorer response". There were 23 nonresponders and 68 responders. Allele G is associated with decreased response to methadone in people with Opioid-Related Disorders as compared to allele A. 18182069 982006932
BDNF rs61888800 GG antidepressants efficacy not stated Outcome with the two drugs was combined for analysis. Not found to be associated with remission vs non-remission. Found to be associated with reduction in HAM-D21 score after adjusting for age, sex, medication, and baseline HAM-D21 score. Genotype GG is associated with increased response to antidepressants, desipramine and fluoxetine in people with Depressive Disorder, Major. 19414708 655387194
BDNF rs6265 CC citalopram efficacy yes The association was with worse treatment outcome over 6 weeks only in clinical subtypes such as melancholic depression. Genotype CC is associated with decreased response to citalopram in people with Depressive Disorder, Major as compared to genotype TT. 19236730 981861657
BDNF rs6265 T methadone efficacy no Response to methadone was measured as the number of urine screens which were positive for opioids during methadone treatment. Please note that alleles have been complemented to the positive strand. Allele T is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele C. 26437921 1449164214
BDNF rs6265 C antipsychotics efficacy no Meta-analysis with 11 studies. The variant was not associated with the total number of responders and non-responders under dominant (p=0.97), recessive (p=0.62) or allelic (p=0.78) models. No significant results were seen when considering only European or Asian patients, or when considering solely chronic schizophrenia patients. Response evaluated according to standardized clinical rating scales such as the Brief Psychiatric Rating Scale (BPRS) or Positive and Negative Syndrome Scale (PANSS). Allele C is not associated with response to antipsychotics in people with schizoaffective disorder or Schizophrenia as compared to allele T. 30181602 1450373368